Your browser doesn't support javascript.

Biblioteca Virtual em Saúde

Brasil

Home > Pesquisa > ()
Imprimir Exportar

Formato de exportação:

Exportar

Email
Adicionar mais destinatários
| |

2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity.

Ott, Gregory R; Wells, Gregory J; Thieu, Tho V; Quail, Matthew R; Lisko, Joseph G; Mesaros, Eugen F; Gingrich, Diane E; Ghose, Arup K; Wan, Weihua; Lu, Lihui; Cheng, Mangeng; Albom, Mark S; Angeles, Thelma S; Huang, Zeqi; Aimone, Lisa D; Ator, Mark A; Ruggeri, Bruce A; Dorsey, Bruce D.
J Med Chem; 54(18): 6328-41, 2011 Sep 22.
Artigo em Inglês | MEDLINE | ID: mdl-21859094
A novel 2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazine scaffold has been designed as a new kinase inhibitor platform mimicking the bioactive conformation of the well-known diaminopyrimidine motif. The design, synthesis, and validation of this new pyrrolo[2,1-f][1,2,4]triazine scaffold will be described for inhibitors of anaplastic lymphoma kinase (ALK). Importantly, incorporation of appropriate potency and selectivity determinants has led to the discovery of several advanced leads that were orally efficacious in animal models of anaplastic large cell lymphoma (ALCL). A lead inhibitor (30) displaying superior efficacy was identified and in depth in vitro/in vivo characterization will be presented.
Selo DaSilva